New biosimilar guide for pharmacists in Australia

Home/Policies & Legislation | Posted 24/05/2019 post-comment0 Post your comment

During the Generic and Biosimilar Medicines Association’s (GBMA) Biosimilar Week, Federal Minister for Health, Greg Hunt, introduced Biosimilar Week 2019 along with the launch of the Biosimilar Hub, which included a set of specific guidelines geared towards pharmacists.

20 AA010933

The GBMA’s Biosimilar Week took place on 29 April to 3 May 2019. The event featured the launch of the 2019 Biosimilar Education Program for healthcare professionals, which was developed collaboratively by representatives across medical specialities, government health experts and the medicines industry. The programme was co-ordinated by GBMA Education, the educational arm of the GBMA, with funding from the Australian Government.

Biosimilar Week was designed as an introduction to a comprehensive three-year programme on the best use of biosimilars. It was supported by an AU$5 million Biosimilar Education Grant from the Australian Government.

In addition, the GBMA launched the Biosimilar Hub, which includes specific guidance for patients, prescribers and pharmacists. The guidance suggests that the savings accrued from biosimilars use ‘could be reinvested into other areas of the Australian healthcare system such as expanded access of existing biological medicines or funding new healthcare treatments’.

In Australia, biologicals or biosimilars deemed substitutable at the pharmacy level by including a notation in the official Pharmaceutical Benefits Schedule known as an ‘a’ flag [1]. These can be dispensing by pharmacists after a compulsory consultation with the patient. When a biosimilar is ‘a’ flagged the pharmacist does not have to consult the prescribing doctor for approval when substituting it for a biological. However, this can only occur if the prescriber has not checked the ‘brand substitution not permitted’ box on the prescription.

As well as educating pharmacists about biosimilars, the guide also suggests that pharmacists can also encourage patients to retain brand and batch number of medicines for future healthcare interactions.

Related article
Australia’s PBAC recommends substitution of adalimumab biosimilars

Reference
1. GaBI Online - Generics and Biosimilars Initiative. Australia’s PBAC recommends substitution of biosimilars [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2019 May 24]. Available from: www.gabionline.net/Biosimilars/General/Australia-s-PBAC-recommends-substitution-of-biosimilars

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2019 Pro Pharma Communications International. All Rights Reserved.

Source: GBMA

comment icon Comments (0)
Post your comment
Related content
Generic ‘skinny’ labelling under threat in the US
Label prescription drugs
Home/Policies & Legislation Posted 05/11/2021
FDA publishes final Q&A on biosimilar development and the BPCI Act
Question-Fimea-V15E29
Home/Policies & Legislation Posted 15/10/2021
FDA voices concerns around drug patents and competition
Patent 1 V13E17
Home/Policies & Legislation Posted 08/10/2021
Most viewed articles
About GaBI
Home/About GaBI Posted 05/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010